acromegalic


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to acromegalic: acromegalic gigantism

ac·ro·me·gal·ic

(ak'rō-mĕ-gal'ik),
Pertaining to or characterized by acromegaly.

ac·ro·me·gal·ic

(ak'rō-mĕ-gal'ik)
Pertaining to or characterized by acromegaly.
References in periodicals archive ?
Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months.
Ultrasonographic measurement of femoral cartilage thickness in acromegalic patients.
As a conclusion, in the differential diagnosis of patients with acromegalic appearance, although rare, pseudoacromegaly should be considered.
In acromegalic patients, hyperphosphatemia can occur as a result of direct stimulation of renal tubular phosphate reabsorption due to increased levels of IGF-1 (1).
It has been reported that apoplexy may occur after head trauma (4), gastric bleeding (5), pituitary testing or treatment with hypothalamic hormones or analogues (6) administration of contrast agents (7), thyroidectomy (8), discontinuation of subcutaneous octreotide (9), and cerebral angiography (10) in acromegalic patients.
Pitutiary apoplexy after subtotal thyroidectomy in an acromegalic patient with a large goiter.
Thus, GH per se may not to be directly responsible for the high sE-selectin serum concentrations observed in acromegalic patients.
Somatuline([R]) Depot has been marketed in the United States by Tercica since August 2007 for the long-term treatment of acromegalic patients who have had an inadequate response to, or cannot be treated with, surgery and/or radiotherapy.
Acromegalic patients are known to have very high blood levels of IGF-1 and reducing these levels to normal is considered the key marker to successful treatment.
Key findings of the study show that 89 percent of acromegalic patients at the highest SOMAVERT dose experienced normalized serum IGF-I at 12 weeks; whereas only 10 percent of the placebo group reached normalized levels at 12 weeks.
Key findings of the study show that 89 percent of acromegalic patients at the highest SOMAVERT dose experienced normalised serum IGF-I at 12 weeks; whereas only 10 percent of the placebo group reached normalised levels at 12 weeks.